13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001703031
Total reported value
$1.7B
$1.7B
25 檔
37.3%
At the close of Q2 2024, Bain Capital Life Sciences Investors, LLC disclosed equity holdings valued at approximately $1.7B, spread across 25 reported holdings.
During Q2 2024, Bain Capital Life Sciences Investors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 22.46% | — | — | |
| 2 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 22.09% | -13.42% | — | |
| 3 | IRON | Disc Medicine Inc | Stock-Other | 8.89% | -0.20% | +36.33% | |
| 4 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 8.56% | -0.64% | +0.72% | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 6.82% | -1.32% | — | |
| 6 | SVRA | Savara Inc | Stock-Other | 6.44% | -2.22% | — | |
| 7 | ANNX | Annexon Inc | Stock-Other | 4.55% | -1.09% | -2.92% | |
| 8 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 2.77% | -0.89% | +6.46% | |
| 9 | TNGX | Tango Therapeutics Inc | Stock-Other | 2.72% | — | — | |
| 10 | SLDB | Solid Biosciences Inc | Stock-Other | 2.51% | -0.54% | — | |
| 11 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.91% | — | — | |
| 12 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 1.56% | — | — | |
| 13 | IPSC | Century Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 14 | CABA | Cabaletta Bio Inc | Stock-Other | 1.35% | +0.84% | +2.02% | |
| 15 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 1.08% | — | — | |
| 16 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.05% | — | -48.76% | |
| 17 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.90% | -0.58% | — | |
| 18 | RPID | Rapid Micro Biosystems Inc-a | Stock-Other | 0.61% | -0.86% | — | |
| 19 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.56% | +0.29% | -2.65% | |
| 20 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.51% | — | — | |
| 21 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.39% | — | +34.93% | |
| 22 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.29% | — | +62.75% | |
| 23 | IVVD | Invivyd Inc | Stock-Other | 0.22% | — | — | |
| 24 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.12% | — | -66.67% | |
| 25 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.10% | -0.05% | — |
According to official SEC Form 13F filings, Bain Capital Life Sciences Investors, LLC reported a total U.S. public equity portfolio value of $1.7B across 25 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, NAMS, IRON) accounted for 37.3% of total reported equity market value during Q2 2024.
During Q2 2024, Bain Capital Life Sciences Investors, LLC's top holdings by market value included NUVL (22.5%)、NAMS (22.1%)、IRON (8.9%). The largest single position, NUVL, represented 22.5% of total portfolio value.
In Q2 2024, Bain Capital Life Sciences Investors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.